Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

AstraZeneca’s Asthma Drug Receives Expanded Indication from FDA

XTALKS VITALS NEWS

Inhaler

The drug is already approved for use in patients over the age of 12 for the treatment of asthma as well as chronic obstructive pulmonary disease (COPD).

Share this!

January 31, 2017 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Symbicort (budesonide/formoterol fumarate dihydrate) for control of asthma in pediatric patients aged six to 12. The drug is already approved for use in patients over the age of 12 for the treatment of asthma as well as chronic obstructive pulmonary disease (COPD).

Clinical trials conducted as part of AstraZeneca’s Childhood Asthma Safety and Efficacy (CHASE) program were used to support the expanded indication for Symbicort. In particular, the CHASE 3 Phase III clinical trial found that the drug was able to improve lung function in pediatric patients, when delivered via a pressurized metered-dose inhaler (pMDI).



These patients enrolled in the clinical trial were previously symptomatic when medicated with low-dose inhaled corticosteroids. AstraZeneca also reported that the safety profile for Symbicort in pediatric patients was similar to that in adults.

“We are pleased to now be able to also offer Symbicort to younger patients in the US, starting at six years of age, helping to control and prevent asthma symptoms,” said Kai Richter, Vice President Respiratory Medical Affairs, AstraZeneca. “Symbicort continues to be a cornerstone of asthma care around the world and it remains a key medicine in our growing respiratory portfolio.”

Symbicort is an inhaled corticosteroid/long-acting beta2-agonist bronchodilator which controls asthma symptoms by reducing inflammation in the lungs and preventing airways from closing. While over 100 countries have approved Symbicort for the regular treatment of asthma, it is not approved for the treatment of acute bronchospasm in the US.

In the US, it is estimated that 6.3 million children 18 years and younger have been diagnosed with asthma. Physical activity can be a common trigger for asthma symptoms, resulting in reduced participation and increased school absences if the condition is left untreated.


Keywords: Asthma, Drug Indication, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA

March 27, 2017 - Pfizer and Merck KGaA’s PD-L1 inhibitor, Bavencio (avelumab), has become the first immunotherapy to be approved by the US Food and Drug Administration (FDA) to treat a rare form of skin cancer, known as metastatic Merkel cell carcinoma (MCC).

Featured In: Biotech News


New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.